Piramal Pharma acquires controlling stake in Yapan Bio

Piramal Pharma Limited (PPL) has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organization (CDMO). The transaction, finalized on August 18, 2026, involved a cash consideration of ₹76 crore (approximately $7.95 million USD).

Following this acquisition, PPL now holds a 74% equity stake in Yapan Bio, transitioning the company from an associate to a subsidiary. Yapan Bio specializes in process development, characterization, and Phase I and II GMP manufacturing for vaccines and biologics.

The move is intended to expand PPL’s presence in the biologics sector and enhance its integrated large molecule CDMO services. Yapan Bio will operate under Piramal Pharma Solutions (PPS) and will support the ADCelerate™ platform, which aims to streamline Phase I antibody-drug conjugate (ADC) development.